← back to search

Philip Chi Lip Kwok

The University of Sydney · AU
Area of research
Pulmonary and Respiratory Medicine · Pharmaceutical Science
Research interest
Research interests include Inhalation and Respiratory Drug Delivery, Drug Solubulity and Delivery Systems, Microencapsulation and Drying Processes, and Aerosol Filtration and Electrostatic Precipitation.
h-index
36
citations
3,518
works
113
NIH funding
primary concept
email

Recent publications

The Gut-Lung Axis, Epigenetics and Respiratory Disease.
2026cited by 0position: contributordoi
Solubilising and Aerosolising Cannabidiol Using Methyl β-Cyclodextrin and Human Serum Albumin.
2025cited by 6position: contributordoi
The anti-biofilm activity of cannabinoids against methicillin-resistant Staphylococcus aureus.
2025cited by 0position: contributordoi
Spray freeze dried cannabidiol with dipalmitoylphosphatidylcholine (DPPC) for inhalation and solubility enhancement.
2024cited by 9position: contributordoi
High-loading cannabidiol powders for inhalation.
2024cited by 8position: contributordoi
Respiratory Delivery of <i>Lacticaseibacillus rhamnosus</i> GG by Vibrating-Mesh and Jet Nebulisation.
2024cited by 1position: contributordoi
Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration
Pharmaceutical Research 2023cited by 41position: lastdoi
Role of Particle Size in Translational Research of Nanomedicines for Successful Drug Delivery: Discrepancies and Inadequacies
Journal of Pharmaceutical Sciences 2023cited by 34position: middledoi
Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration.
2023cited by 26position: contributordoi
Role of Particle Size in Translational Research of Nanomedicines for Successful Drug Delivery: Discrepancies and Inadequacies.
2023cited by 23position: contributordoi
Editorial: Strategies to overcome the barriers to effective inhaled treatments.
2023cited by 0position: contributordoi
Phage–Antibiotic Therapy as a Promising Strategy to Combat Multidrug-Resistant Infections and to Enhance Antimicrobial Efficiency
Antibiotics 2022cited by 106position: middledoi
Advances and future perspectives in epithelial drug delivery
Advanced Drug Delivery Reviews 2022cited by 86position: middledoi
Phage-Antibiotic Therapy as a Promising Strategy to Combat Multidrug-Resistant Infections and to Enhance Antimicrobial Efficiency.
2022cited by 77position: contributordoi
Advances and future perspectives in epithelial drug delivery.
2022cited by 53position: contributordoi
Recent advances in drug delivery to the central nervous system by inhalation.
2022cited by 10position: contributordoi
A 3D printed human upper respiratory tract model for particulate deposition profiling
International Journal of Pharmaceutics 2021cited by 38position: middledoi
Administration of dry powders during respiratory supports
Annals of Translational Medicine 2021cited by 15position: middledoi
A 3D printed human upper respiratory tract model for particulate deposition profiling.
2021cited by 12position: contributordoi
In vitro-in vivo correlation of cascade impactor data for orally inhaled pharmaceutical aerosols.
2021cited by 12position: contributordoi
Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19.
2021cited by 12position: contributordoi
Nebulised Isotonic Hydroxychloroquine Aerosols for Potential Treatment of COVID-19.
2021cited by 10position: contributordoi
Co-spray dried hydrophobic drug formulations with crystalline lactose for inhalation aerosol delivery.
2021cited by 10position: contributordoi
Administration of dry powders during respiratory supports.
2021cited by 7position: contributordoi
Spray-Dried Powder Formulation of Capreomycin Designed for Inhaled Tuberculosis Therapy.
2021cited by 6position: contributordoi
Advances in Inhalation Drug Delivery.
2021cited by 1position: contributordoi
In vitro-in vivo correlation of pharmaceutical aerosols.
2021cited by 0position: contributordoi
Pharmaceutical Applications of 3D Printing
Additive manufacturing 2020cited by 161position: middledoi
Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization
Bioengineering & Translational Medicine 2020cited by 59position: middledoi
Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization.
2020cited by 38position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Hak‐Kim Chan · The University of Sydney14 papers (2012–2023)Jenny K.W. Lam · New York University8 papers (2013–2020)Michael Y.T. Chow · University College London7 papers (2013–2019)Wanling Liang · Guangdong University of Technology4 papers (2013–2018)A. James Mason · Johns Hopkins University3 papers (2013–2015)Lifeng Kang · The University of Sydney3 papers (2020–2021)Waiting Tai · The University of Sydney3 papers (2020–2023)Patricia A. Tang · University of Calgary3 papers (2012–2021)Rachel Yoon Kyung Chang · The University of Queensland3 papers (2020–2022) · 2 papers (2017–2020) · 2 papers (2019–2020)Suzanne M. D’Addio · Merck & Co., Inc., Rahway, NJ, USA (United States)2 papers (2012–2013)Robert K. Prud’homme · Princeton University2 papers (2012–2013) · 2 papers (2017–2017) · 2 papers (2019–2023)Jian Li · Biomedicine Discovery Institute2 papers (2020–2020)Yingshan Qiu · Xiamen University2 papers (2017–2017)John Gar Yan Chan · The University of Sydney2 papers (2012–2013)Grona Chen · University of Sydney1 papers (2020–2020)Ivan Chun Hang Lam · Nuffield Orthopaedic Centre1 papers (2020–2020)